Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.34 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | GHSR | Q92847 | 2/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | PRKACA | P17612 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
| ▸ | MST1R | Q04912 | 1/20 | 0.31 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.31 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7357256 | 0.91 | MEN1 (0.38) | MAPK14LRRK2AGTR1BTKMEN1 | |
| SCHEMBL8103012 | 0.91 | MEN1 (0.38) | MAPK14LRRK2AGTR1BTKMEN1 | |
| SCHEMBL4373864 | 0.88 | MAPK14 (0.32) | MAPK14LRRK2BRD4 | |
| SCHEMBL5095796 | 0.82 | BAZ2B (0.41) | LRRK2KDRBRD4 | |
| SCHEMBL5095801 | 0.82 | BAZ2B (0.41) | LRRK2KDRBRD4 | |
| SCHEMBL5109722 | 0.81 | F12 (0.38) | — | |
| SCHEMBL5109718 | 0.81 | F12 (0.38) | — | |
| SCHEMBL6610168 | 0.81 | CYP11B1 (0.39) | TDP2GSK3BLMNA | |
| SCHEMBL14287073 | 0.80 | PGR (0.37) | TDP2MEN1KMT2ABRD4 | |
| SCHEMBL13592447 | 0.80 | GRIA1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1736468-A2 | Isatin derivatives with neurotrophic activity useful in the treatment of diseases mediated by the nerve growth factor (NGF) activation | NeuroSearch A/S (DK) | 2006-12-27 | — | — | EP | claimed |
| US-20060229311-A1 | Isatine derivatives with neurotrophic activity | GROENBORG METTE | 2006-10-12 | — | — | US | claimed |
| JP-2003520851-A | — | — | 2003-07-08 | — | — | JP | claimed |
| US-20030040518-A1 | Isatine derivatives with neurotrophic activity | ANIONA APS (DK) | 2003-02-27 | — | — | US | claimed |
| EP-1255734-A1 | ISATINE DERIVATIVES WITH NEUROTROPHIC ACTIVITY | NeuroSearch A/S (DK) | 2002-11-13 | — | — | EP | claimed |
| WO-2001055110-A1 | ISATINE DERIVATIVES WITH NEUROTROPHIC ACTIVITY | NEUROSEARCH A/S (DK) | 2001-08-02 | — | — | WO | claimed |
| US-7595336-B2 | Isatine derivatives with neurotrophic activity | NEUROSEARCH A/S (DK) | 2009-09-29 | — | — | US | disclosed |
| US-7282511-B2 | Isatine derivatives with neurotrophic activity | NEUROSEARCH A/S (DK) | 2007-10-16 | — | — | US | disclosed |
| EP-1736468-A2 | Isatin derivatives with neurotrophic activity useful in the treatment of diseases mediated by the nerve growth factor (NGF) activation | NeuroSearch A/S (DK) | 2006-12-27 | — | — | EP | disclosed |
| US-20060229311-A1 | Isatine derivatives with neurotrophic activity | GROENBORG METTE | 2006-10-12 | — | — | US | disclosed |
| US-20030040518-A1 | Isatine derivatives with neurotrophic activity | ANIONA APS (DK) | 2003-02-27 | — | — | US | disclosed |
| EP-1255734-A1 | ISATINE DERIVATIVES WITH NEUROTROPHIC ACTIVITY | NeuroSearch A/S (DK) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001055110-A1 | ISATINE DERIVATIVES WITH NEUROTROPHIC ACTIVITY | NEUROSEARCH A/S (DK) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229311-A1 | Isatine derivatives with neurotrophic activity | BDNF, NTRK2, NGF | MAPK14 481/4885LRRK2 201/4885AGTR1 3546/4885 |
| US-20030040518-A1 | Isatine derivatives with neurotrophic activity | BDNF, NTRK2, NGF | MAPK14 481/4885LRRK2 201/4885AGTR1 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.